Reviewing DaVita (NYSE:DVA) & Global Cord Blood (NYSE:CORBF)

DaVita (NYSE:DVA) and Global Cord Blood (NYSE:CORBF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Insider and Institutional Ownership

90.1% of DaVita shares are owned by institutional investors. 1.4% of DaVita shares are owned by company insiders. Comparatively, 0.5% of Global Cord Blood shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

DaVita has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500.

Profitability

This table compares DaVita and Global Cord Blood’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DaVita	5.70%	64.42%	4.63%
Global Cord Blood	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations for DaVita and Global Cord Blood, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	0	2	1	0	2.33
Global Cord Blood	0	0	0	0	N/A

DaVita currently has a consensus target price of $118.50, indicating a potential downside of 10.75%. Given DaVita’s higher probable upside, equities analysts clearly believe DaVita is more favorable than Global Cord Blood.

Earnings & Valuation

This table compares DaVita and Global Cord Blood’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$12.14 billion	0.96	$691.53 million	$7.40	17.94
Global Cord Blood	$196.12 million	N/A	$79.04 million	N/A	N/A

DaVita has higher revenue and earnings than Global Cord Blood.

Summary

DaVita beats Global Cord Blood on 10 of the 10 factors compared between the two stocks.

About DaVita

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

About Global Cord Blood

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.